From: Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin
Protective strategy
Dexrazoxane
Continuous infusion
Crossover
Patient Number
8
11
10
Peak hS-TnT > 5 ng/ml
0
7
Peak hs-TnT > 10 ng/ml
6
3
1